aTyr Pharma, Inc. (ATYR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.50-1.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
aTyr Pharma is advancing its lead drug efzofitimod for lung disease. Operating losses improved from -$26.7M to -$11.4M in recent quarters. The company manages cash burn while pursuing regulatory progress. Success could unlock value in a high-risk biotech.
The company remains unprofitable with ongoing negative cash flow. It faces Nasdaq delisting risks and failed a key Phase 3 trial. Future earnings are expected to stay negative. These issues could prevent recovery and dilute shareholder value.
The market prices a very low fair value of $0.12 per share reflecting high risk and ongoing losses. Our view aligns with this cautious valuation given uncertain drug approval and financial challenges.
Breaks if: lack of positive regulatory or clinical progress through 2026
Breaks if: failure to regain Nasdaq compliance or delisting occurs
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is in a challenging phase, focusing on drug development while managing significant operating losses and cash burn.
The current valuation reflects a premium compared to peers, driven by the optionality of its drug development pipeline. However, the market appears to be cautious, given the company's loss-making status and recent challenges.
Management is making progress in reducing operating losses and cash burn, but the overall financial performance remains neutral. The recent completion of enrollment in a key study is a positive sign, but the company still faces high risk in its sector.
The thesis hinges on the outcomes of upcoming clinical trials and management's ability to navigate operational challenges. Additionally, broader sector performance and economic conditions will impact investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no current threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Respond to Nasdaq deficiency notice regarding bid price below $1.00 per share and maintain listing compliance.
Newly stated in 2026-Q2. The company received a Nasdaq deficiency notice due to the bid price closing below $1.00 per share for 30 consecutive business days. No further updates on resolution or progress were provided in subsequent quarters, indicating limited progress on this regulatory priority.
“Received Nasdaq deficiency notice for bid price below $1.00 per share for 30 consecutive business days.”
Breaks if: operating loss worsens beyond -$11.4M per quarter
Implement cost saving measures including workforce reduction to reduce operating expenses and conserve capital.
Stated as a priority in 3 of last 3 quarters. Management has implemented a workforce reduction of about 60% and expects to reduce annualized operating expenses by approximately $13M starting Q4 2026. Operating expenses decreased from $20.3M in 2025-Q4 to $10.9M in 2026-Q2, and net loss improved from -$13.9M to -$10.3M over the same period. The trajectory shows progress in managing losses and cash burn consistent with management's stated cost discipline.
“Workforce reduction of approximately 60% to conserve capital and align resources.”
“Operating expenses were $11.4M in 2026-Q1, with plans to manage losses.”
“Operating expenses were $20.3M in 2025-Q4, reflecting ongoing cost management efforts.”
In the next 1 to 3 years, ATYR's success will depend on its drug development progress and market conditions. Not investment advice.